dailynews.ascopubs.org/do/role-mach...
dailynews.ascopubs.org/do/role-mach...
@pateloncology.bsky.social
@pateloncology.bsky.social
@adesaimd.bsky.social @pgrivasmdphd.bsky.social @sagarlonialmd.bsky.social @pateloncology.bsky.social
@pateloncology.bsky.social
@pateloncology.bsky.social
Nice use of existing basket studies by @pateloncology.bsky.social @eladsharonmd.bsky.social Razelle Kurzrock et al
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
Nice use of existing basket studies by @pateloncology.bsky.social @eladsharonmd.bsky.social Razelle Kurzrock et al